AWKN-SND-14

AWKN-SND-14 is a pre-clinical drug candidate developed by Awakn Life Sciences, consisting of a series of novel serotonin, dopamine, and noradrenaline modulators. It is being investigated for trauma-related mental health disorders, with a primary focus on Post-Traumatic Stress Disorder (PTSD). The program was previously referred to as Awakn's aminoindane new chemical entity program. AWKN-SND-14 is designed to promote pro-social behavior—enhancing trust, empathy, and social bonding—which are critical elements in addressing PTSD. The aim is to provide a potentially improved safety profile compared to current investigational PTSD treatments and help individuals rebuild relationships and engage more effectively in therapy[1][4][6]. Mechanistically, the drug modulates neurotransmitter activity by enhancing the release of serotonin (SERT), dopamine (DAT), and noradrenaline[2]. As of early 2025, the program remains in pre-clinical development.

Other names

Awakn aminoindane new chemical entity program